|
Rapid Communication
Dynamics of viral load and anti-SARS-CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19
Kyoung-Ho Song, Dong-Min Kim, Hyunju Lee, Sin Young Ham, Sang-Min Oh, Hyeonju Jeong, Jongtak Jung, Chang Kyung Kang, Ji Young Park, Yu Min Kang, Ji-Yeon Kim, Jeong Su Park, Kyoung Un Park, Eu Suk Kim, Hong Bin Kim
Korean J Intern Med. 2021;36(1):11-14. Published online November 25, 2020
Recently, the number of patients with coronavirus disease 2019 (COVID-19) who have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), via the reverse transcription polymerase chain reaction (RT-PCR) test, after recovery has increased; this has caused a dilemma regardin..
|
|
|
Hemato-oncology
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
Mi Hwa Heo, Hee Kyung Kim, Hansang Lee, Ji-Yeon Kim, Jin-Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Korean J Intern Med. 2019;34(5):1100-1106. Published online March 16, 2018
Background/Aims: We conducted a retrospective analysis of the clinical activity of fulvestrant in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) previously treated with endocrine therapy and/or chemotherapy..
|
|
|
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
Sehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2017;32(3):514-522. Published online April 14, 2017
Background/Aims: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based t..
|
|
|
